INMB - NASDAQ

INmune Bio, Inc.

INmune Bio, Inc.

INMBยทNASDAQ

$1.89

-1.3%
HealthcareBiotechnology

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$50.25M
EPS-2.1100
P/E Ratio-2.21
Earnings Date03/26/2026
INmune Bio, Inc.

INmune Bio, Inc. Fair Value Envelope

INMB ยท NASDAQ

Our analysis suggests that INMB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.89, this represents a potential HIDDEN relative to our calculated worth for INmune Bio, Inc..

HIDDEN
Intrinsic Value
Current Price: $1.89

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$28.7M
+ Cash & Equivalents$20.9M
Firm Value-$7.8M
- Debt$384.0K
Equity Value-$8.2M
/ Shares Outstanding26,585,258B
DCF Value-$0
OVERVALUED BY 116%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$16.7M
-$8.3M
-$4.2M
-$2.1M
-$1.0M
-$521.3K
-$260.6K
-$130.3K
-$65.2K
-$32.6K
Maintenance CapEx
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
Owner Earnings
-$16.7M
-$8.3M
-$4.2M
-$2.1M
-$1.0M
-$521.3K
-$260.6K
-$130.3K
-$65.2K
-$32.6K
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$15.4M
-$7.2M
-$3.3M
-$1.5M
-$709.5K
-$328.5K
-$152.1K
-$70.4K
-$32.6K
-$15.1K
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your INMB research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.